Furthermore, CPT‐Low was administered even prior to the tumor implantation, which similarly sensitized MC38 tumors to anti‐PD1 antibody (Figure 2D) and augmented intratumoral CD8+ T‐cell function (Figure 2E). The gene discussed is CD8A; the disease is neoplasm.